1. Home
  2. SATL vs PRTA Comparison

SATL vs PRTA Comparison

Compare SATL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Satellogic Inc.

SATL

Satellogic Inc.

HOLD

Current Price

$6.89

Market Cap

968.5M

Sector

Technology

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.81

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SATL
PRTA
Founded
2010
2012
Country
United States
Ireland
Employees
154
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
968.5M
539.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SATL
PRTA
Price
$6.89
$10.81
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$5.50
$19.00
AVG Volume (30 Days)
14.8M
453.1K
Earning Date
05-12-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$85.89
$1,111.38
Revenue Next Year
$57.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.26
$4.32
52 Week High
$8.02
$11.69

Technical Indicators

Market Signals
Indicator
SATL
PRTA
Relative Strength Index (RSI) 64.85 67.15
Support Level $3.18 $9.69
Resistance Level N/A $10.90
Average True Range (ATR) 0.95 0.40
MACD 0.06 0.10
Stochastic Oscillator 67.26 96.87

Price Performance

Historical Comparison
SATL
PRTA

About SATL Satellogic Inc.

Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: